Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma - Concepedia

Concepedia

Publication | Closed Access

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

53

Citations

17

References

2014

Year

David Schiff, Santosh Kesari, John de Groot, Tom Mikkelsen, Jan Drappatz, Thomas Coyle, Lisa Fichtel, Bruce A. Silver, Ian Walters, David A. Reardon

Investigational New Drugs

Neuro-oncologyHuman FibronectinGliomaMedicinePathologyHigh-grade GliomasCancer TreatmentPhase 2Radiation OncologyOncologyCell BiologyRecurrent GlioblastomaCancer Growth

References

	Year	Citations

Page 1

Page 1